Wedge Play for some HealthCare exposure. Solid Volume runner as well.
EVIO * Fib retracement bottomed at $0.70US and now at 0.79 uptick * Uptick started and CCI moved up on day chart to buy * Cannabis Industry getting traction with CBD sales * Test lab approvals CA, OR (trace metals, solvents, pesticides, THC) * 50% partnership with Keystone Labs Canada Viewers come to own conclusion.
around 200 systems sold all over world and evolving... complex tooling and system integration
Biogen's (344.10 at close at the date of this writing) and Eisai's recent success with BAN24O1, an experimental medication for Alzheimer's which is currently in mid-stage clinical trials, in addition to a recent price target raise by Citi, and overall bullish analyst sentiment led to a rally between July 6-9, 2018. Although the clinical trial's success was...
$CELZ Remains unstoppable into the Mid May Bio Conference where they will be presenting, DD below in links.
$CELZ is currently on a clear and clean breakout in anticipation of the May 18th- 21st Presentation at the American Urological Association Convention in San Francisco. An 8K was released recently showing that shares were issued at .10 and as high as .30 levels The following link shows that the CEO has been buying on the way up as...
$CELZ broke above prior high on the last leg after a release of 8-Ks showing the clearing up of the rest of the company's debt and notes. Item 1.01 Entry into a Material Definitive Agreement Effective April 11, 2018, Creative Medical Technology Holdings, Inc. (the “ Company ”) amended promissory notes issued by it and by its operating subsidiary, Creative...
DD below in link
Oh Novanta. So many possibilities for such a great company. Please forgive the maddening amount of clustered lines. The primary trend line is massive and seemingly unstoppable for a reason. Even though it's gone parabolic, its story is rock solid and almost sexy with everything they have a hand in. As a leader in medical and advanced, industrial markets, Novanta...
With brand recognition and consistent sales in place, Mazor has stated that 2018 will be a transition year for them, not growth. Therefore, expect the company to aim for stability as it continues to spread its products. Per the last call: "2018 is expected to be a year of transition and our performance is expected to be driven primarily by increased revenues from...
Acadia Pharmaceuticals has shown a downward swing during the past 2 business days or so. Before that it was on a very big run, which on my opinion was due to the high demand and the low buy/sell price. It will soon find support around the 32.67 up to the 38 zone (see the purple channel) based on the past downswing which i just stated. In the very near future it...
Initial move of around 100% has had some time to consolidate and soak away remaining supply which has been thinning considerably since the first move. Recently the green bars have been finding much less supply therefore the possibility of a significant move is increasing. If the topside break occurs then 12.0c would be the target This medical cannabis company...
Reposting as it didn't post properly the first time $DCTH Highlights for the first quarter of 2017 and the recent weeks include: First quarter 2017 revenue of $0.74 million, an increase of 100% compared with revenue of $0.37 million in prior year quarter. CHEMOSAT treatment milestone set by SPIRE Southampton Hospital in the U.K. with more than 100 CHEMOSAT...
Nothing entirely new to report. Closed above last major resistance and still continues to stair step in the right direction. I think it should be noted and I didn't mention it before but the corporations who took a stake in the company in the last two months: Maxim Group set a $4.00 price target on shares of ContraVir Pharmaceuticals and gave the stock a “buy”...
$CTRV to present at the 2017 Marcum MicroCap Conference being held June 15-16. 2017, at the Grand Hyatt New York in New York City .60s on this stock has always been a massive support level since 2014. Go back far enough and you can see where the stock hits .60 and then moves back to multi-dollars. This CEO doesn't do R/S's he is an old school OG who knows how to...
I have been following this Mazor story for over a year, since Medtronic took a stake in them. They are selling their robotic systems well in the US and europe. With Medtronic financial and sales support, as well as their updated systems, this year should be a breakout one. Current target is 60, although longer term I believe it will be much higher (unless they...
GHOST TECHNICAL PREDICTION FOR TSXV:EMC BASED ON ECONOMICAL EVENTS AND KEY BREAKOUT AREAS
I'm seeing some bashing of this company on a few other outlets. I think one thing new investors into VDRM need to realize is that greatness takes time. If you bought into it at 0.06-0.07 because somebody told you it was going to run to a $1 overnight, that's all on the trader and not on the stock. If you look at the chart, this is a very healthy company with a...